Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.

Perez Stachowski, JavierRial Crestelo, DavidMoreno Zamora, AnaCabello, NoemiRyan, PabloEspinosa Aguilera, NuriaBisbal, OtiliaVivancos Gallego, Maria JesusNuñez, Maria JoseTroya, JesusDominguez, MontserratSierra, Julian Olalla2023-05-032023-05-032022-08-252077-0383http://hdl.handle.net/10668/21338Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNAenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/HIVantiretroviral treatmentsevere immunosuppressionUse of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.research article36078925open access10.3390/jcm11174994PMC9457350https://www.mdpi.com/2077-0383/11/17/4994/pdf?version=1661496715https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457350/pdf